title: MiR-214 regulates the pathogenesis of patients with coronary artery disease by targeting VEGF.
abstract: Circulating microRNAs (miRNAs) in patient body fluids have recently been considered to hold the potential of being novel disease biomarkers and drug targets. We aimed to investigate the correlation between the levels of circulating miR-214 and the expression of vascular endothelial growth factor (VEGF) in the pathogenesis of coronary heart disease patients to further explore the mechanism involved in the vasculogenesis. Three different cohorts, including 13 acute myocardial infarction patients, 176 angina pectoris patients, and 127 control subjects, were enrolled to investigate the expression levels of circulating miR-214 in patients with myocardial ischemia and also the relationship between plasma miR-214 and severity of coronary stenosis. Plasma miR-214 levels of participants were examined by real-time quantitative PCR. Simultaneously, plasma cardiac troponin I concentrations were measured by ELISA assays. We further detected the correlation of miR-214 and VEGF by molecular and animal assays. MiR-214 was enriched in not only diseased endothelial progenitor cells (EPCs) but also the plasma of coronary artery disease (CAD) patients. Besides, we found out miR-214 was able to suppress VEGF expression and EPC activities. Reporter assays confirmed the direct binding and repression of miR-214 to the 39-UTR of VEGF mRNA. Knockdown of miR-214 not only restored VEGF levels and angiogenic activities of diseased EPCs in vitro, but also further promoted blood flow recovery in ischemic limbs of mice. Circulating miR-214 may be a new biomarker for CAD and as a potential diagnostic tool. And increased miR-214 level may be used to predict the presence and severity of coronary lesions in CAD patients.
authors.affiliation: Department of Cardiology, Wuxi No. 2 People's Hospital, The Affiliated Hospital of Nanjing Medical University, Wuxi, 214002, Jiangsu, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Jin
authors.forename: Cheng-Jian
authors.initials: CJ
authors.lastname: Yang
authors.forename: Xin
authors.initials: X
authors.lastname: Xu
authors.forename: Jia-Ning
authors.initials: JN
authors.lastname: Cao
authors.forename: Qiu-Ting
authors.initials: QT
authors.lastname: Feng
authors.forename: Jun
authors.initials: J
authors.lastname: Yang
mesh_terms: D020413:3' Untranslated Regions; D000818:Animals; D001665:Binding Sites; D016022:Case-Control Studies; D049109:Cell Proliferation; D002478:Cells, Cultured; D003324:Coronary Artery Disease / Q000378:metabolism* / Q000473:pathology; D066026:Endothelial Progenitor Cells / Q000502:physiology; D015870:Gene Expression; D006614:Hindlimb / Q000098:blood supply; D006801:Humans; D007511:Ischemia / Q000378:metabolism; D008819:Mice, Nude; D035683:MicroRNAs / Q000502:physiology*; D018919:Neovascularization, Physiologic; D034622:RNA Interference; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics* / Q000378:metabolism
chemical_list: D020413:3' Untranslated Regions; C547397:MIRN214 microRNA, human; D035683:MicroRNAs; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A